Informacija diabetikams:

Information for diabetics:

Pacientams diabetikams rekomenduojama tikrinti gliukozs koncentracij kraujyje.

Monitoring of glucose concentrations is recommended in diabetic patients.

Pacientams diabetikams rekomenduojama tikrinti gliukozės koncentraciją kraujyje.
http://www.emea.europa.eu/

Monitoring of glucose concentrations is recommended in diabetic patients.
http://www.emea.europa.eu/

Pranestuose atvejuose laktatin acidoz vis pirma pasitaik pacientams diabetikams,

Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.

Diabetikams, vartojantiems irbesartano, hiperkalemija pasireisk dazniau negu vartojantiems placebo.

Investigations:Hyperkalaemia occurred more often in diabetic patients treated with irbesartan than with placebo.

Diabetikams gali tekti keisti insulino ir geriamųjų preparatų nuo cukrinio diabeto dozę.
http://www.emea.europa.eu/

In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.
http://www.emea.europa.eu/

Serotonino atbulinio patekimo į neuroną inhibitorių vartojantiems diabetikams gali kisti gliukozės kiekio kraujyje reguliavimas.
http://www.emea.europa.eu/

In patients with diabetes, treatment with an SSRI may alter glycaemic control.
http://www.emea.europa.eu/

Hipertenzija sergantiems diabetikams, kuriems buvo lėtinis inkstų nepakankamumas ir aiški proteinurija, pasireiškė ir toliau nurodytos nepageidaujamos reakcijos.
http://www.emea.europa.eu/

In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, the following additional adverse reactions were reported in > 2% of patients and in excess of placebo:
http://www.emea.europa.eu/

Hipertenzija sergantiems diabetikams, kuriems buvo ltinis inkst nepakankamumas ir aiski proteinurija, pasireisk ir toliau nurodytos nepageidaujamos reakcijos.

Hypertension and type 2 diabetes with renal disease: in addition to the adverse drug reactions mentioned under hypertension, in diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i. e., uncommon) but in excess of placebo.

Pranestuose atvejuose laktatin acidoz vis pirma pasitaik pacientams diabetikams, gydomiems metforminu, kuriems buvo zymus inkst funkcijos nepakankamumas.

Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.

Pranestais atvejais laktatin acidoz vis pirma pasitaik pacientams diabetikams, gydomiems metforminu, kuriems buvo zymus inkst funkcijos nepakankamumas.

Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.

Praneštais atvejais laktatinė acidozė visų pirma pasitaikė pacientams diabetikams, gydomiems metforminu, kuriems buvo žymus inkstų funkcijos nepakankamumas.
http://www.emea.europa.eu/

Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
http://www.emea.europa.eu/

Praneštuose atvejuose laktatinė acidozė visų pirma pasitaikė pacientams diabetikams, gydomiems metforminu, kuriems buvo žymus inkstų funkcijos nepakankamumas.
http://www.emea.europa.eu/

Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
http://www.emea.europa.eu/

Sprendzaint is pranest atvej, laktatin acidoz vis pirma pasitaik pacientams diabetikams, gydytiems metforminu, turintiems zym inkst funkcijos nepakankamum.

Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.

Pranestais atvejais laktatin acidoz vis pirma pasitaik pacientams diabetikams, gydomiems metforminu, kuriems buvo zymus inkst funkcijos nepakankamumas.Laktatins acidozs

Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.

Sprendžaint iš praneštų atvejų, laktatinė acidozė visų pirma pasitaikė pacientams diabetikams, gydytiems metforminu, turintiems žymų inkstų funkcijos nepakankamumą.
http://www.emea.europa.eu/

Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
http://www.emea.europa.eu/

Vartojant tiazidini diuretik, gali tapti pastebimas latentinis cukrinis diabetas, kisti gliukozs toleravimas, todl diabetikams gali reikti keisti geriamj preparat nuo cukrinio diabeto arba insulino doz.

Thiazide therapy may impair glucose tolerance.In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.Latent diabetes mellitus may become manifest during thiazide therapy.

Hipertenzija sergantiems diabetikams, kuriems buvo ltinis inkst nepakankamumas ir aiski proteinurija, pasireisk ir toliau nurodytos nepageidaujamos reakcijos.J atsirado 2% irbesartano vartojusi pacient ir buvo daznesns negu vartojusiems placebo.

None of these increases were associated with identifiable clinical musculoskeletal events.Hypertension and type 2 diabetes with renal disease: in addition to the adverse drug reactions mentioned under hypertension, in diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i. e., uncommon) but in excess of placebo.In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, the following additional adverse reactions were reported in 2% of patients and in excess of placebo:

Hipertenzija sergantiems diabetikams, kuriems buvo ltinis inkst nepakankamumas ir aiski proteinurija, pasireisk ir toliau nurodytos nepageidaujamos reakcijos.J atsirado 2% irbesartano vartojusi pacient ir buvo daznesns negu vartojusiems placebo.

In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, the following additional adverse reactions were reported in 2% of patients and in excess of placebo:

Poveikio gliukozs ir lipid apykaitai jis nedar.Antianginin ir antiisemin poveik ivabradinas sukl ir diabetikams (N = 457) .Jiems preparato poveikis buvo saugus tiek pat kaip kitiems tiriamiesiems.5. 2 Farmakokinetins savybs

No influence on glucose or lipid metabolism was observed.The antianginal and anti-ischaemic efficacy of ivabradine was preserved in diabetic patients (n = 457) with a similar safety profile as compared to the overall population.